Abstract
ABSTRACTNovel silica nanoparticles (SLN) chemically modified with hyaluronic acid (HA) were developed by exploiting the drug loading property of SLN and the tumor-targeting ability of HA to construct a tumor-targeting paclitaxel (PTX) delivery system (HA-SLN) for potential breast cancer therapy. The experimental results indicated that PTX loading into the HA-SLN was favorable to cancer therapy. PTX-loaded HA-SLN nanoparticles increased the accumulation of PTX in MCF-7 breast cancer cells via CD44 receptor–mediated endocytosis and exhibited superior anticancer activity in vitro. In vivo anticancer efficacy assay revealed that HA-SLN possessed preferable anticancer ability that exhibited minimal toxic side effects of PTX and strong tumor-suppression potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
